Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2025-03-12 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 40% confidence The document is a NI 52-109 Form 52-109FV1 certification by the CEO of a “venture issuer” certifying the accuracy and completeness of the annual filings (AIF, financial statements, MD&A). It is neither the full annual report nor an MD&A or audit report itself, nor any other specific announcement. It is a regulatory certification form filed with securities authorities, falling under miscellaneous regulatory filings. Hence, it is classified under the fallback category Regulatory Filings (RNS).
2025-03-12 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a standard NI 52-109FV1 certification by the CFO of Theralase Technologies Inc. for its venture issuer annual filings (AIF, financial statements, MD&A). It is a statutory certificate form, not the annual report itself or its financial content. It doesn’t fit categories like 10-K/Annual Report, IR, ER, or any governance or management announcement. As a standalone regulatory compliance filing without content of the report, it falls under the general Regulatory Filings category.
2025-03-12 English
Annual MD&A - English.pdf
Management Reports Classification · 92% confidence The document is titled “Management’s Discussion and Analysis of Financial Condition and Operations,” covers the year ended December 31, 2024, and contains narrative commentary on financial results, business strategy, and outlook (forward-looking statements). It is not merely an announcement of report availability nor a full audited financial statement or annual report; rather, it is the MD&A section filed under continuous disclosure rules. This matches the Management Reports (MDA) category.
2025-03-12 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 90% confidence The document is an independent auditor’s report accompanied by the audited consolidated financial statements (balance sheet, income statement, cash flow, notes) for the year ended December 31, 2024 and 2023. It does not include broader management discussion and analysis or other sections typical of a full annual report (10-K), nor is it a brief announcement. It is a standalone audit report with financial statements, matching the definition of Audit Report / Information (AR). FY 2024
2025-03-12 English
News release - English.pdf
Earnings Release Classification · 92% confidence The document is a corporate press release announcing and summarizing the company's audited annual financial statements for the twelve-month period ended December 31, 2024. It provides key financial highlights (revenue, net loss, margins), a condensed statement of operations, and details on a conference call for investors. This format and content align with an Earnings Release rather than a full Annual Report or a mere report publication notice. Therefore, it should be classified as an Earnings Release (ER). FY 2024
2025-03-12 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter from McCarthy Tétrault LLP consenting to the use of its legal opinions in a pricing supplement for a short form base shelf prospectus. It is not an earnings release, annual report, management discussion, or any of the other specific categories. It is a miscellaneous regulatory filing submitted to securities commissions to satisfy prospectus requirements. No dedicated category exists for prospectus legal opinions, so the fallback category “Regulatory Filings (RNS)” applies.
2025-03-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.